Golrang Pharmaceutical Investment Company

What Golrang Pharmaceutical Investment Company does

Golrang Pharmaceutical Investment Company (GPI) is a privately held Iranian pharmaceutical investment holding company, established in 2010 by the diversified Golrang Industrial Group. GPI operates 14+ wholly-owned subsidiaries organized along the full pharmaceutical value chain — Active Pharmaceutical Ingredient (API) manufacturing (Soroush Mana Pharmed, Hasti Aria Shimi), finished dosage-form production (Faran Shimi, Varian Pharmed, Abian Pharmed), dietary and medicinal supplements (Arian Salamat Sina, Pharmed Salamat Sina, Abian Darou, Venda Pharmed, Pajuhesh Goostaran Taghziehye Asan), pharmaceutical distribution (Salamat Pakhsh Hasti), and commercial intermediation (Tivan Tamin Pars, Aban Darman Behboud) — plus a dedicated Golrang Drug and Health Innovation Center for R&D.

GPI's product surface spans generic finished pharmaceuticals (tablets, capsules, injectables), APIs and chemical intermediates, and an expanding consumer health brand portfolio including FemiCare (vaginal moisturizer), Multi Vegan (natural multivitamin, via an exclusive partnership with France's Holistica), MagniFort (prenatal supplement), Max Pro (whey protein isolate), FastMeal Renal LP (renal nutrition), and complex generics such as Lisdexamfetamine Mesylate (Otons) and Abemaciclib 100/125 mg. The group's go-to-market combines a captive domestic distribution arm serving Iranian pharmacies and hospitals, direct enterprise export of APIs and finished products to international buyers, and an export channel operated through Faran Shimi and Varian Pharmed.

The revenue model is a hybrid of pharmaceutical product sales and transaction-fee distribution revenue, supported by multiple knowledge-based (دانش بنیان) company designations that unlock R&D incentives under Iran's regulatory framework. Ownership is wholly held by the Golrang Industrial Group; no external institutional investors or PE/VC funding are disclosed. Marketing reach extends through the corporate website, LinkedIn, Instagram, the Aparat video platform, the bilingual monthly "Parsiavoshan" newsletter, an internal teacher academy, scientific product sessions, and Iran Pharma exhibitions. In January 2026, GPI proposed and convened the first session of the Iran-India Joint Chamber of Commerce Pharmaceutical Commission to formalize trade, technology transfer, and B2B cooperation with Indian pharmaceutical bodies.

Name

Golrang Pharmaceutical Investment Company

Legal name

Golrang Pharmaceutical Investment Company (شرکت سرمایه گذاری دارویی گلرنگ)

Website

https://golrangpi.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Golrang Pharmaceutical Investment Company (GPI) is an Iranian private pharmaceutical holding established in 2010 by the Golrang Industrial Group, managing 14+ wholly-owned subsidiaries spanning API manufacturing, finished drug products, nutritional supplements, and pharmaceutical distribution for domestic and export markets.

Ownership category

akta.pro rank

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical finished products, APIs, and supplements: The group generates revenue through the manufacture and sale of pharmaceutical finished products, active pharmaceutical ingredients (APIs), nutritional supplements, and drug distribution services across domestic and export markets.
2. Pharmaceutical distribution: Through subsidiary Salamat Pakhsh Hasti, the group operates pharmaceutical distribution channels serving Iran's pharmacy and healthcare networks.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Golrang Pharmaceutical Investment Company (GPI) operates as a pharmaceutical investment holding company managing 14+ subsidiaries across the full pharmaceutical value chain. It manufactures active pharmaceutical ingredients (APIs), finished pharmaceutical products in multiple dosage forms (tablets, capsules, injectables), and dietary/medicinal supplements; distributes drugs domestically via its subsidiary Salamat Pakhsh Hasti; and exports APIs and finished products to international markets.

Product overview

Golrang Pharmaceutical Investment Company (GPI) operates as a pharmaceutical investment holding company established in 1389 (2010) by Golrang Industrial Group. GPI does not offer a unified software product or platform; rather, its portfolio consists of pharmaceutical products and health services delivered through 14 subsidiaries organized across the pharmaceutical value chain. The group's product categories include final pharmaceutical products (Faran Shimi, Abian Pharmed, Varian Pharmed), active pharmaceutical ingredients (Soroush Mana Pharmed, Hasti Arya Shimi), dietary and medicinal supplements (Arian Salamat Sina, Farned Salamat Sina, Abian Darou, Faran Pharmed, Vanda Pharmed, Pajuhesh Gostaran Taghziehye Asan), pharmaceutical distribution (Salamat Pakhsh Hasti), and export services. Named consumer health brands include FemiCare (vaginal moisturizer), Multi Vegan (natural multivitamin), MagniFort (prenatal supplement), Max Pro (whey protein isolate), and FastMeal Renal LP (renal nutrition). A Golrang Drug and Health Innovation Center drives R&D across new pharmaceutical and health products.

Differentiator

Problem solved

Functional benefit

Products and services

• Final Pharmaceutical Products (محصولات نهایی دارویی) Finished pharmaceutical dosage forms (tablets, capsules, injectables) manufactured by GPI subsidiaries Faran Shimi, Abian Pharmed, and Varian Pharmed; supplied to pharmacies, hospitals, and exported to international buyers.
• Active Pharmaceutical Ingredients / API (ماده موثر دارویی) Active Pharmaceutical Ingredients (APIs) manufactured by GPI subsidiaries Soroush Mana Pharmed and Hasti Aria Shimi; covers the upstream segment of the pharmaceutical value chain from raw material to finished product.
• Dietary and Medicinal Supplements (مکمل‌های غذایی و دارویی) Nutritional and dietary supplements produced by multiple GPI subsidiaries (Arian Salamat Sina, Farned Salamat Sina, Abian Darou, Faran Pharmed, Vanda Pharmed, Pajuhesh Gostaran Taghziehye Asan); sold via pharmacy channels.
• Pharmaceutical Distribution (پخش دارو) Pharmaceutical distribution and delivery services across Iran, operated through the Salamat Pakhsh Hasti subsidiary to serve pharmacies, hospitals, and healthcare networks.
• Pharmaceutical Export Services (صادرات) Export of APIs and finished pharmaceutical products manufactured by GPI subsidiaries to international buyers; managed by subsidiaries Varian Pharmed and Faran Shimi.
• FemiCare (فمی کر) Vaginal Moisturizer Non-hormonal vaginal moisturizer containing hyaluronic acid, aloe vera, tea tree oil, calendula, and glycerin; produced by Arian Salamat Sina for treatment of vaginal dryness and atrophy; packaged in single-dose applicators (7 units per pack).
• MagniFort (مگنیفورت) Prenatal Supplement Dietary supplement containing magnesium, vitamins B1, B6, D3, and K2; addresses common nutritional deficiencies during pregnancy and supports maternal and fetal health.
• Max Pro (مکس پرو) Whey Protein Isolate Whey protein isolate supplement (13.5g WPI, 1.8g L-glutamine, 0.3g inulin prebiotic, vitamin B6 per 18g sachet); produced by Pajuhesh Gostaran Taghziehye Asan for athletes (muscle growth/recovery), ICU patients (prevention of protein-energy malnutrition), and elderly (sarcopenia prevention).
• FastMeal Renal LP (فست میل رنال ال پی) Specialized nutritional supplement for non-dialysis chronic kidney disease (CKD) patients; produced by Pajuhesh Gostaran Taghziehye Asan; contains controlled protein, low potassium/phosphorus/sodium, MUFA, omega-3 fatty acids, soluble fiber (inulin), vitamins D3, B complex, L-carnitine, and antioxidants.
• Multi Vegan (مولتی وگان) Natural Multivitamin 100% natural multi-vitamin-mineral supplement produced by French company Holistica, exclusively imported and distributed in Iran by Arian Salamat Sina; contains natural micronutrients sourced from food, including Shiitake mushroom extract for immune support, with vitamins and minerals packaged in separate blisters.
• Lisdexamfetamine Mesylate (لیزدگزامفتامین مزیلات) Generic CNS Drug Generic CNS/neurology drug, a prodrug of dextroamphetamine with sympathomimetic action; available in 10, 20, 30, 50, and 70 mg doses; used for ADHD and moderate-to-severe binge eating disorder (BED) in adults. Brand name: Otons.
• Abemaciclib (البوسیکلیب) 100/125 mg Oncology Drug Generic CDK4/6 inhibitor oral capsule (100/125 mg) for treatment of advanced or metastatic HR-positive, HER2-negative breast cancer; works by preventing cell cycle progression from G1 to S phase.
• Fertility Supplement (مکمل باروری) Female fertility supplement containing Myo-Inositol and D-Chiro-Inositol in a 40:1 ratio with lemon flavor; intended to improve egg quality, regulate menstrual cycles, reduce insulin resistance, and increase IVF success rates.

Quantifiable outcome

• 14+ pharmaceutical subsidiaries across the value chain, exporting significant production volumes to other countries

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Iran-India Joint Chamber of Commerce — Pharmaceutical CommissioncoreStrategic or Co-development Partner · 15 October 1404The first session of the Pharmaceutical Commission of the Iran-India Joint Chamber of Commerce was held on 15 Dey 1404 (January 4, 2026) at the proposal of Golrang Pharmaceutical Investment Group. The commission aims to create a formal, transparent platform for structured cooperation between Iranian and Indian pharmaceutical industries, beyond raw material sourcing and currency transfer issues. Goals include facilitating joint trade, organizing company participation in specialized exhibitions, obtaining group visas, organizing specialized tours, and establishing formal connections with Indian pharmaceutical bodies including IDMA and Pharmexcil. Mission areas include creating infrastructure for technology transfer, supporting joint investment opportunities, and facilitating B2B interactions between pharmaceutical companies of both countries.
• Food and Drug Organization of Iran (سازمان غذا و دارو)coreOthers
• Syndicate of Owners of Iranian Human Pharmaceutical Industries (سندیکای صاحبان صنایع داروهای انسانی ایران)coreOthers
• Golrang Industrial Group (گروه صنعتی گلرنگ)coreOthers
• Holistica (France)minorGTM or Marketing PartnerFrench company whose Multivegan product — a natural multivitamin-mineral supplement containing shiitake mushroom extract — is exclusively represented in Iran by subsidiary Arian Salamat Sina, which serves as the exclusive representative of Holistica in Iran.
• Novartis (Switzerland)minorOthers

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Cipla: India's largest pharmaceutical company by domestic market share, with strong API and generics franchises across global markets. Comparable to GPI as an India-side counterparty referenced in the 2026 Iran-India Joint Chamber of Commerce Pharmaceutical Commission partnership.

Direct peers

• Barakat Pharmaceutical Group: Vertically integrated Iranian pharmaceutical group with APIs, finished products, and biotech operations. Closely comparable to GPI's structure as a diversified domestic pharma holding company targeting Iranian self-sufficiency and export markets.
• CinnaGen: Leading Iranian biotech and pharmaceutical company specializing in biosimilars, monoclonal antibodies, and specialty therapeutics. Comparable to GPI as a domestic knowledge-based pharmaceutical manufacturer with R&D-intensive capabilities and export activity.
• Darou Pakhsh Pharmaceutical Manufacturing Company: Iran's largest pharmaceutical manufacturer, covering APIs through finished dosage forms across multiple therapeutic categories. Directly comparable to GPI as a domestic vertically integrated pharma group competing for the same Iranian pharmacy, hospital, and export channels.
• Actoverco: Iranian pharmaceutical manufacturer and part of the Barakat Group, producing finished dosage forms for domestic and export markets. Comparable to GPI as a direct domestic competitor in finished pharmaceutical manufacturing with similar distribution channels.
• Tofigh Daru: Iranian pharmaceutical manufacturer producing APIs and finished dosage forms. Directly comparable to GPI's API subsidiaries (Soroush Mana Pharmed, Hasti Aria Shimi) and finished-drug subsidiaries in the domestic Iranian generics market.

Emerging players

• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with API and finished generics capabilities across global markets. Relevant peer given GPI's newly established Iran-India pharmaceutical cooperation platform and Dr. Reddy's role as a potential technology transfer or B2B partner.

Regional players

• Exir Pharmaceutical: Iranian pharmaceutical manufacturer producing generic finished products. Comparable to GPI as a domestic peer operating in the same Iranian generic market with overlapping distribution channels and export ambitions.
• TPICO (Tolid Darou): Iranian pharmaceutical manufacturer focused on finished generics and contract manufacturing. Comparable to GPI as a domestic Iranian peer competing in finished dosage forms across similar therapeutic categories and pharmacy distribution channels.
• Sobhan Oncology: Iranian specialty pharmaceutical company focused on oncology and hematology products. Comparable to GPI's high-complexity generic oncology offering (Abemaciclib) as a domestic peer competing in the same specialty Iranian therapeutic market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/golrangpi
• YouTubeaparat.com/GPI
• LinkedInlinkedin.com/company/golrang-pharmaceutical-investment
• Instagraminstagram.com/golrangpi
• Facebookfacebook.com/golrangpi

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Golrang Pharmaceutical Investment Company